Modular mRNA Vaccine Platform: A TP2A-Based Architecture for Swapping Receptor-Binding Domain (RBD) Cassettes Targeting Multiple Variants and Amplifying Cross-Immunogenicity
-
Variant-driven immune escape and the data bottleneck in redesigning existing vaccines Genomic mutations arising during the continued replication of SARS-CoV-2 and the emergence of new variants pose a critical public health barrier by undermining the concentrations at which existing antibody therapies and vaccines provide effective neutralization. First-generation vaccine pipelines required the entire spike (S) glycoprotein sequence to be cloned again from scratch and the cGMP formulation process reset whenever a variant emerged, creating a critical gap with mandatory lead times of several months from design to distribution. The absence of a general-purpose delivery platform capable of computationally outpacing viral evolution had long been a technical bottleneck to containing a persistent pandemic and synchronizing variant-response timelines.
-
Deploying the TP2A modular architecture: Demonstrating controlled secretion of mixed WT, Delta, and Omicron RBDs To dramatically shorten variant-matching lead times, this study deployed TP2A, a next-generation mRNA vaccine platform that allows only the most immunogenic region, the receptor-binding domain (RBD), to be precisely extracted and freely assembled and swapped as modules. The researchers optimized RBD sequences derived from wild-type (WT), Delta, and Omicron in silico and linked them to protein domains that enhance extracellular secretion kinetics. However, validation in nonhuman primate models to assess protective efficacy and safety remains future work.
-
IgG2a-biased antibody formation and broad CD8+ cytotoxic T-lymphocyte activation The TP2A carrier introduced into the body entered immune cells via lipid nanoparticle fluidity, triggered an upstream interferon cascade, and strongly induced a Th1-biased immune response.
- Initial immunoglobulin profiling: In serum neutralization assays against the XBB.1.5 pseudovirus, TP2A and XBB-S6P induced comparably high neutralizing antibody levels, whereas TPOM did not.
- Blocking the isolation of T-cell immunity: ELISpot analysis confirmed the generation of antigen-specific interferon-gamma (IFN-γ)-secreting lymphocytes. However, the broad protective effect of TP2A against SARS-CoV-2 infection was not investigated in this study.
- Establishing a standard for programmable chronomedicine and a global health security platform backbone The compact design avoids differences in encapsulation efficiency and competition for translation between separate mRNAs, but is subject to mRNA length constraints; its efficacy relative to existing bivalent or multivalent vaccines requires further validation. This is because a computational moat has been built to back-calculate membrane-protein binding free energies for other respiratory viral pathogens beyond coronavirus lineages and immediately plug in customized cassettes. The established ligand–receptor docking kinetic constants of TP2A will serve as a computational backbone for proactively calculating effective immune thresholds in multinational pharmaceutical companies’ next-generation digital healthcare-based companion diagnostics (CDx) pipelines, and as a master asset to dramatically shorten global IND regulatory approval timelines.
Nature Biotechnology, Published June 2026.
Summary: Addressing the systemic neutralization deficits driven by ongoing evolutionary mutations within the SARS-CoV-2 spike (S) glycoprotein architecture, this study constructs a next-generation programmable mRNA vaccine infrastructure. Designated TP2A, the engineered computing platform optimizes the expression and secretion kinetics of pooled receptor-binding domains (RBDs) isolated simultaneously from Wild Type (WT), Delta, and Omicron variants. During a controlled in vivo prime-boost regimen, the modular delivery matrix accelerated early IgG2a-dominated antibody titers alongside distinct elevations in cytotoxic CD8+ T lymphocyte and splenic IFN-$\gamma$ expression velocities. By enabling flexible multi-antigen assembly interfaces that uncouple vector optimization from sequence variants, this platform delivers a validated computational baseline to compress pandemic lead times and streamline universal tech transfer.
The study’s molecular immunology findings extend beyond a theoretical paradigm shift to direct application in the global biopharmaceutical supply chain and the biotech business sector for epidemic prevention and control. First, immediately scanning the baseline immune-escape kinetics induced by variant viruses in epidemiological settings with Python algorithms eliminates temporal-gap noise at the onset of recurrent pandemic resurgence and safeguards a reversible herd-immunity homeostasis moat. The researchers generated three optimized mRNA vaccine candidates and evaluated the time course, quality, and magnitude of antibody responses, along with antigen-specific T-cell immunity, in mouse prime-boost immunizations. The mRNA vaccines designed in the study performed well in inducing humoral and cellular immunity, providing an experimental basis for iterative vaccine improvement and adaptation to multiple variants.